

## IN THE CLAIMS

1. (Currently Amended) An isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of a ~~TEM protein selected from the group consisting of potassium inwardly rectifying channel, subfamily J, member 8; vascular cell adhesion molecule 1; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; hypothetical protein MGC5508; syndecan 2 (heparan sulfate proteoglycan 1, cell surface associated, fibroglycan); hypothetical protein BC002942; uncharacterized hematopoietic stem/progenitor cells protein MDS032; FAT tumor suppressor homolog 1 (Drosophila); G protein coupled receptor 4; amyloid beta (A4) precursor protein (protease nexin II, Alzheimer disease); tumor necrosis factor receptor superfamily, member 25 (translocating chain association membrane protein); major histocompatibility complex, class I, A; degenerative spermatocyte homolog; lipid desaturase (Drosophila); matrix metalloproteinase 25; prostate stem cell antigen; melanoma cell adhesion molecule; G protein-coupled receptor Hs.23016; protocadherin beta 9; matrix metalloproteinase 14 (membrane inserted); scotin; chemokine (C-X-C motif) ligand 14; murine retrovirus integration site 1 homolog; integrin, alpha 11; interferon, alpha; inducible protein (clone IFI-6-16); CLSTN11240 protein; H factor (complement) like; tweety homolog 2 (Drosophila); transient receptor potential cation channel, subfamily V, member 2; hypothetical protein PRO1855; sprouty homolog 4 (Drosophila); accessory protein BAP31; integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51); gap junction protein, alpha 4, 37kDa (connexin 37); calsyntenin 1; solute carrier family 26, member 6; family with sequence similarity 3, member C; immunoglobulin heavy constant gamma 3 (C3m marker); hephaestin; hypothetical protein DKFZp761D0211; cisplatin resistance related protein CRR9p; hypothetical protein IMAGE3455200; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE881791; hypothetical protein MGC15523; prostaglandin I2 (prostacyclin) receptor (IP); CD164 antigen; sialomucin; putative G protein coupled~~

~~receptor GPCR41; DKEZP566H073 protein; platelet derived growth factor receptor, alpha polypeptide; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa; CD151 antigen; platelet derived growth factor receptor, beta polypeptide; KIAA0102 gene product; B7 homolog 3; solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1); endothelin receptor type B; defender against cell death 1; transmembrane, prostate androgen induced RNA; Notch homolog 3 (Drosophila); lymphotxin beta (TNF superfamily, member 3); chondroitin sulfate proteoglycan 4 (melanoma-associated); lipoma HMGIC fusion partner; hypothetical protein similar to ankyrin repeat containing protein AKR1; SDR1 short chain dehydrogenase/reductase 1; PCSK7 proprotein convertase subtilisin/kexin type 7; Homo sapiens mRNA, cDNA DKEZp686D0720 (from clone DKEZp686D0720); FAP fibroblast activation protein, alpha; MCAM melanoma cell adhesion molecule; and CRELD1 cysteine rich with EGF-like domains 1.~~

2. (Original) The molecule of claim 1 which is an intact antibody molecule.
3. (Original) The molecule of claim 1 which is a single chain variable region (ScFv).
4. (Original) The molecule of claim 1 which is a humanized antibody.
5. (Original) The molecule of claim 1 which is a human antibody.
6. (Original) The molecule of claim 1 which is bound to a cytotoxic moiety.
7. (Original) The molecule of claim 1 which is bound to a therapeutic moiety.
8. (Original) The molecule of claim 1 which is bound to a detectable moiety.
9. (Original) The molecule of claim 1 which is bound to an anti-tumor agent.
10. (Currently Amended) A method of inhibiting neoangiogenesis comprising:

administering to a subject in need thereof an effective amount of an isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of a ~~TEM protein selected from the group consisting of: potassium inwardly rectifying channel, subfamily J, member 8; vascular cell adhesion molecule 1; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; hypothetical protein MGC5508; syndecan 2 (heparan sulfate proteoglycan 1, cell surface associated, fibroglycan); hypothetical protein BC002942; uncharacterized hematopoietic, stem/progenitor cells protein MDS032; FAT tumor suppressor~~

~~homolog 1 (Drosophila); G protein coupled receptor 4; amyloid beta (A4) precursor protein (protease nexin II, Alzheimer disease); tumor necrosis factor receptor superfamily, member 25 (translocating chain association membrane protein); major histocompatibility complex, class I, A; degenerative spermatocyte homolog; lipid desaturase (Drosophila); matrix metalloproteinase 25; prostate stem cell antigen; melanoma cell adhesion molecule; G protein-coupled receptor Hs.23016; protocadherin beta 9; matrix metalloproteinase 14 (membrane inserted); scotin; chemokine (C-X-C motif) ligand 14; murine retrovirus integration site 1 homolog; integrin, alpha 11; interferon, alpha; inducible protein (clone IFI 6-16); CLST 11240 protein; H factor (complement) like; tweety homolog 2 (Drosophila); transient receptor potential; cation channel, subfamily V, member 2; hypothetical protein PRO1855; sprouty homolog 4 (Drosophila); accessory protein BAP31; integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51); gap junction protein, alpha 4, 37kDa (connexin 37); calyntenin 1; solute carrier family 26, member 6; family with sequence similarity 3, member C; immunoglobulin heavy constant gamma 3 (G3m marker); hephaestin; hypothetical protein DKFZp761D0211; cisplatin resistance related protein CRR9p; hypothetical protein IMAGE3455200; Homo sapiens mRNA full length insert cDNA clone EUROTOIMAGE881791; hypothetical protein MGC15523; prostaglandin I2 (prostacyclin) receptor (IP); CD164 antigen; sialomucin; putative G protein coupled receptor GPCR41; DKFZP566H073 protein; platelet derived growth factor receptor, alpha polypeptide; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa; CD151 antigen; platelet derived growth factor receptor, beta polypeptide; KIAA0102 gene product; B7 homolog 3; solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1); endothelin receptor type B; defender against cell death 1; transmembrane, prostate androgen induced RNA; Notch homolog 3 (Drosophila); lymphotoxin beta (TNF superfamily, member 3) chondroitin sulfate proteoglycan 4 (melanoma associated); lipoma HMGIC fusion partner; hypothetical protein similar to ankyrin repeat containing protein AKR1; SDR1 short chain dehydrogenase/reductase 1; PCSK7 proprotein convertase subtilisin/kexin type 7; Homo sapiens mRNA, cDNA~~

~~DKFZp686D0720 (from clone DKFZp686D0720); FAP fibroblast activation protein, alpha; MCAM melanoma cell adhesion molecule; and CRELD1 cysteine rich with EGF-like domains 1~~, whereby neoangiogenesis is inhibited.

11. (Original) The method of claim 10 wherein the subject bears a vascularized tumor.
12. (Original) The method of claim 10 wherein the subject has polycystic kidney disease.
13. (Original) The method of claim 10 wherein the subject has diabetic retinopathy.
14. (Original) The method of claim 10 wherein the subject has rheumatoid arthritis.
15. (Original) The method of claim 10 wherein the subject has psoriasis.
16. (Currently Amended) A method for inhibiting tumor growth in a subject bearing a tumor, comprising:

administering to the subject an effective amount of an isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of ~~a TEM protein selected from the group consisting of potassium inwardly rectifying channel, subfamily J, member 8; vascular cell adhesion molecule 1; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; hypothetical protein MGC5508; syndecan 2 (heparan sulfate proteoglycan 1, cell surface associated, fibroglycan); hypothetical protein BC002942; uncharacterized hematopoietic, stem/progenitor cells protein MDS032; FAT tumor suppressor homolog 1 (Drosophila); G protein-coupled receptor 4; amyloid beta (A4) precursor protein (protease nexin II, Alzheimer disease); tumor necrosis factor receptor superfamily, member 25 (translocating chain association membrane protein); major histocompatibility complex, class I, A; degenerative spermatocyte homolog; lipid desaturase (Drosophila); matrix metalloproteinase 25; prostate stem cell antigen; melanoma cell adhesion molecule; G protein-coupled receptor Hs\_23016; protocadherin beta 9; matrix metalloproteinase 14 (membrane inserted); scotin; chemokine (C-X-C motif)~~

~~ligand 14; murine retrovirus integration site 1 homolog; integrin, alpha 11; interferon, alpha ; inducible protein (clone IFI 6-16); CLST 11240 protein; H factor (complement) like; tweety homolog 2 (Drosophila); transient receptor potential; cation channel, subfamily V, member 2; hypothetical protein PRO1855; sprouty homolog 4 (Drosophila); accessory protein BAP31; integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51); gap junction protein, alpha 4, 37kDa (connexin 37); calyxtenin 1; solute carrier family 26, member 6; family with sequence similarity 3, member C; immunoglobulin heavy constant gamma 3 (G3m marker); hephaestin; hypothetical protein DKEZp761D0211; cisplatin resistance related protein CRP9p; hypothetical protein IMAGE3455200; Homo sapiens mRNA full length insert cDNA clone EUROIIMAGE881791; hypothetical protein MGC15523; prostaglandin I2 (prostaeyclin) receptor (IP); CD164 antigen; sialomucin; putative G protein coupled receptor GPCR41; DKEZP566H073 protein; platelet derived growth factor receptor, alpha polypeptide; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa; CD151 antigen; platelet derived growth factor receptor, beta polypeptide; KIAA0102 gene product; B7 homolog 3; solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1); endothelin receptor type B; defender against cell death 1; transmembrane, prostate androgen induced RNA; Notch homolog 3 (Drosophila); lymphotoxin beta (TNF superfamily, member 3) chondroitin sulfate proteoglycan 4 (melanoma associated); lipoma HMGIC fusion partner; hypothetical protein similar to ankyrin repeat containing protein AKR1; SDR1 short chain dehydrogenase/reductase 1; PCSK7 proprotein convertase subtilisin/kexin type 7; Homo sapiens mRNA; cDNA DKEZp686D0720 (from clone DKEZp686D0720); FAP fibroblast activation protein, alpha; MCAM melanoma cell adhesion molecule; and CRELD1 cysteine rich with EGF like domains 1, whereby the growth of the tumor is consequently inhibited.~~

17 to 35. (Cancelled)

36. (Currently Amended) A method of identifying regions of neoangiogenesis in a patient, comprising:

administering to a patient a molecule comprising an antibody variable region which specifically binds to an extracellular domain of a protein, wherein said molecule is bound to a detectable moiety, said protein ~~selected from the group consisting of potassium inwardly rectifying channel, subfamily J, member 8; vascular cell adhesion molecule 1; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; hypothetical protein MGC5508; syndecan 2 (heparan sulfate proteoglycan 1, cell surface associated, fibroglycan); hypothetical protein BC002942; uncharacterized hematopoietic, stem/progenitor cells protein MDS032; FAT tumor suppressor homolog 1 (Drosophila); G protein coupled receptor 4; amyloid beta (A4) precursor protein (protease nexin II, Alzheimer disease); tumor necrosis factor receptor superfamily, member 25 (translocating chain association membrane protein); major histocompatibility complex, class I, A; degenerative spermatocyte homolog; lipid desaturase (Drosophila); matrix metalloproteinase 25; prostate stem cell antigen; melanoma cell; adhesion molecule; being G protein-coupled receptor Hs.23016; protocadherin beta 9; matrix; metalloproteinase 14 (membrane inserted); scotin; chemokine (C-X-C motif) ligand 14; murine retrovirus integration site 1 homolog; integrin, alpha 11; interferon, alpha; inducible protein (clone IFI 6-16); CLST 11240 protein; H factor (complement) like; tweety homolog 2 (Drosophila); transient receptor potential; cation channel, subfamily V, member 2; hypothetical protein PRO1855; sprouty homolog 4 (Drosophila); accessory protein DAP31; integrin, alpha V (vitronectin receptor; alpha polypeptide, antigen CD51); gap junction protein, alpha 4, 37kDa (connexin 37); calsyntenin 1; solute carrier family 26, member 6; family with sequence similarity 3, member C; immunoglobulin heavy constant gamma 3 (G3m marker); hephaestin; hypothetical protein DKFZp761D0211; cisplatin resistance related protein CRR9p; hypothetical protein IMAGE3455200; Homo sapiens mRNA full length insert cDNA clone EUROIDIMAGE881791; hypothetical protein MGC15523; prostaglandin I2 (prostaeyclin) receptor (IP); CD164 antigen; sialomucin; putative G protein coupled receptor GPCR41; DKFZP566H073 protein; platelet derived growth factor receptor, alpha polypeptide;~~

~~NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa; CD151 antigen; platelet derived growth factor receptor, beta polypeptide; KIAA0102 gene product; B7 homolog 3; solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1); endothelin receptor type B; defender against cell death 1; transmembrane, prostate androgen induced RNA; Notch homolog 3 (Drosophila); lymphotxin beta (TNF superfamily, member 3); chondroitin sulfate proteoglycan 4 (melanoma associated); lipoma HMGIC fusion partner; hypothetical protein similar to ankyrin repeat containing protein AKR1; SDR1 short chain dehydrogenase/reductase 1; PCSK7 proprotein convertase subtilisin/kexin type 7; Homo sapiens mRNA, cDNA DKFZp686D0720 (from clone DKFZp686D0720); FAP fibroblast activation protein, alpha; MCAM melanoma cell adhesion molecule; and CRELD1 cysteine rich with EGF like domains 1;~~

detecting the molecule bound to the detectable moiety in the patient, thereby identifying regions of neoangiogenesis in the patient.

37. (Currently Amended) A method of screening for neoangiogenesis in a patient, comprising:

contacting a body fluid collected from a patient with a molecule comprising an antibody variable region which specifically binds to an extracellular domain of ~~a protein selected from the group consisting of: potassium inwardly rectifying channel, subfamily J, member 8; vascular cell adhesion molecule 1; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; hypothetical protein MGC5508; syndecan 2 (heparan sulfate proteoglycan 1, cell surface associated, fibroglycan); hypothetical protein BC002942; uncharacterized hematopoietic stem/progenitor cells protein MDS032; FAT tumor suppressor homolog 1 (Drosophila); G protein coupled receptor 4; amyloid beta (A4) precursor protein (protease nexin II, Alzheimer disease); tumor necrosis factor receptor superfamily, member 25 (translocating chain association membrane protein); major histocompatibility complex, class I, A; degenerative spermatocyte homolog; lipid desaturase (Drosophila); matrix metalloproteinase 25; prostate stem cell antigen; melanoma cell adhesion molecule; G protein-coupled receptor Hs.23016; protocadherin beta 9; matrix metalloproteinase 14 (membrane inserted); scotin; chemokine (C-X-C~~

~~motif) ligand 14; murine retrovirus integration site 1 homolog; integrin, alpha 11; interferon, alpha ; inducible protein (clone IFI 6-16); CLST 11240 protein; H factor (complement) like; tweety homolog 2 (Drosophila); transient receptor potential ; cation channel, subfamily V, member 2; hypothetical protein PRO1855; sprouty homolog 4 (Drosophila); accessory protein BAP31; integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51); gap junction protein, alpha 4, 37kDa (connexin 37); ealsyntenin 1; solute carrier family 26, member 6; family with sequence similarity 3, member C; immunoglobulin heavy constant gamma 3 (C3m marker); hephaestin; hypothetical protein DKFZp761D0211; cisplatin resistance related protein CRR9p; hypothetical protein IMAGE3455200; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE881791; hypothetical protein MGC15523; prostaglandin I2 (prostacyclin) receptor (IP); CD164 antigen; sialomucin; putative G protein coupled receptor GPCR41; DKFZP566H073 protein; platelet derived growth factor receptor, alpha polypeptide; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa; CD151 antigen; platelet derived growth factor receptor, beta polypeptide; KIAA0102 gene product; B7 homolog 3; solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1); endothelin receptor type B; defender against cell death 1; transmembrane, prostate androgen induced RNA; Notch homolog 3 (Drosophila); lymphotoxin beta (TNF superfamily, member 3); chondroitin sulfate proteoglycan 4 (melanoma associated); lipoma HMGIC fusion partner; hypothetical protein similar to ankyrin repeat containing protein AKR1; SDR1 short chain dehydrogenase/reductase 1; PCSK7 proprotein convertase subtilisin/kexin type 7; Homo sapiens mRNA, cDNA DKFZp686D0720 (from clone DKFZp686D0720); FAP fibroblast activation protein, alpha; MCAM melanoma cell adhesion molecule; and GRELD1 cysteine rich with EGF like domains 1;~~

detecting material in the body fluid that is cross-reactive with the molecule, wherein detection of cross-reactive material indicates neo-angiogenesis in the patient.

38-54.(Cancelled)